Rallybio Corporation
NASDAQ · us_market
No AI insight generated yet for this ticker.
Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. The company has a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases, as well as collaboration agreement with Johnson & Johnson to provide therapeutic solutions for pregnant individuals at risk of fetal and neonatal alloimmune thrombocytopenia. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-05-13 | -1.20 | -1.46 | -21.67% |
| 2026-03-16 | -1.17 | -1.52 | -29.55% |
| 2025-11-06 | -1.56 | 2.88 | +284.62% |
| 2025-08-07 | -1.96 | -1.76 | +10.20% |
| 2025-05-08 | -2.28 | -1.68 | +26.32% |
| 2025-03-13 | -2.30 | -2.00 | +13.04% |
| 2024-11-07 | -2.82 | -2.08 | +26.24% |
| 2024-08-08 | -2.86 | -2.96 | -3.39% |
| 2024-05-09 | -3.68 | -3.76 | -2.17% |
| 2024-03-12 | -3.44 | -4.00 | -16.12% |
| 2023-11-09 | -3.98 | -3.60 | +9.61% |
| 2023-08-08 | -3.77 | -3.68 | +2.27% |
| 2023-05-09 | -3.72 | -3.44 | +7.53% |
| 2023-03-06 | -4.92 | -3.68 | +25.21% |
| 2022-11-07 | -4.32 | -4.80 | -11.11% |
| 2022-08-08 | -4.88 | -4.56 | +6.56% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| RLYB | +53.67% | +37.65% | +163.48% | +531.99% |
| XLV | +2.97% | -4.83% | -3.44% | +12.62% |
| Alpha (stock − sector) | +50.70% | +42.48% | +166.93% | +519.37% |